---
title: "Pantginis Reiterates Buy on Nuvectis, Citing Ciprocopan Approval and Pipeline Diversification; Price Target Maintained at $39"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293645130.md"
description: "H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Nuvectis Pharma with an unchanged $39 price target. The recommendation cites the global approval of ciprocopan (NXP100) in China for PNH, demonstrating superior efficacy and safety. Additionally, licensing deals for NXP100 and NXP200 diversify Nuvectis's pipeline beyond oncology into complement-mediated diseases, supported by promising trial data and pending applications."
datetime: "2026-07-23T15:25:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293645130.md)
  - [en](https://longbridge.com/en/news/293645130.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293645130.md)
---

# Pantginis Reiterates Buy on Nuvectis, Citing Ciprocopan Approval and Pipeline Diversification; Price Target Maintained at $39

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Nuvectis Pharma. The associated price target remains the same with $39.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Joseph Pantginis has given his Buy rating due to a combination of factors, primarily the clinical and regulatory validation gained from the first global approval of ciprocopan (NXP100) in China for treatment-naïve PNH. This approval, supported by a Phase 3 trial showing superior efficacy and favorable safety versus Soliris, underscores the differentiated profile of NXP100 as a once-daily oral Factor B inhibitor and strengthens confidence in Nuvectis’s ex-China development plans.

He also highlights that Nuvectis’s licensing of NXP100 and NXP200 from Haisco transforms the company from a single-asset oncology story into a more diversified, late-stage platform in both complement-mediated diseases and oncology. With additional potential catalysts including a pending China application for NXP100 in C5-experienced PNH, ongoing trials in IgAN and lupus nephritis, and early but promising data for NXP200 in multiple BRAF-mutant cancers, Pantginis sees attractive upside potential, supporting his unchanged $39 price target and Buy recommendation.

### Related Stocks

- [NVCT.US](https://longbridge.com/en/quote/NVCT.US.md)
- [002653.CN](https://longbridge.com/en/quote/002653.CN.md)

## Related News & Research

- [BUZZ-Nuvectis Pharma tumbles on deep-discounted $100 mln share sale](https://longbridge.com/en/news/291276054.md)
- [Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock | NVCT Stock News](https://longbridge.com/en/news/291214614.md)
- [Zura Bio posts corporate overview highlighting tibulizumab dual IL-17/BAFF bispecific program in Phase 2 development](https://longbridge.com/en/news/295531903.md)
- [Nuvectis licenses ex-China rights to Haisco’s NXP100, NXP200 in deal worth up to USD 1.42 billion](https://longbridge.com/en/news/290428280.md)
- [Nu E Power closes oversubscribed private placement, raising $3.86 million](https://longbridge.com/en/news/295717394.md)